Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|70 Years Old Patients and Over|After One Line of Chemotherapy With Trastuzumab
Interventions: DRUG: lapatinib + capecitabine
Sponsor: UNICANCER
Collaborators: GlaxoSmithKline